Moving From What to Why: Adding Mechanistic Context to HCI-Detected Phenotypes with Multi-Omics
This blog entry is contributed by Carla Neiser from Sapient Bioanalytics.
Cell-based Assays and High-content Imaging in Antisense-oligonucleotide Development
Antisense oligonucleotides are revolutionizing precision medicine by enabling targeted ...
Unique Benefits of Using High-content Imaging in Non-clinical R&D
High-content imaging, or high-content screening, is a transformative approach to ...
In Vitro Assays in the Nutraceutical Industry
Table of Contents Overview of the Nutraceutical Industry The Current Role of In Vitro ...
Understanding DNM1L Disease: Diagnosis and Challenges
Recently, PhenoVista has been working with the DNM1L Foundation - a community of ...
Exosomes in Fibrosis Research and Drug Development
Exosome research is unlocking new potential in the treatment of fibrosis, offering hope ...
Mitophagy in Neurodegenerative Diseases
Mitophagy in Neurodegenerative Diseases: Implications for Drug Development and ...
Liver Organoids in Drug Discovery
Table of Contents Introduction to Liver Organoids Liver Organoids in Drug Discovery and ...
On In Vivo vs. In Vitro Models
Explore the differences between in vivo and in vitro models and their roles in drug ...